Literature DB >> 15765193

Recurrent spontaneous "neuroleptic malignant syndrome" in the absence of neuroleptic medication in probable dementia with Lewy bodies.

K E Weber, R A Linker, R Lorenz, W Muellges, M Naumann, K Reiners, J Classen.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15765193     DOI： 10.1007/s00415-005-0804-1

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  14 in total

1.  Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies.

Authors:  K Kanemaru; N Kameda; H Yamanouchi
Journal:  Neurology       Date:  2000-05-09       Impact factor: 9.910

2.  Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older.

Authors:  T Rahkonen; U Eloniemi-Sulkava; S Rissanen; A Vatanen; P Viramo; R Sulkava
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

3.  Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

Authors:  C Ballard; J Grace; I McKeith; C Holmes
Journal:  Lancet       Date:  1998-04-04       Impact factor: 79.321

4.  Neuroleptic malignant syndrome-like condition in multiple system atrophy.

Authors:  M Konagaya; Y Goto; Y Matsuoka; T Konishi; Y Konagaya
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

5.  Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation.

Authors:  S Minoshima; N L Foster; A A Sima; K A Frey; R L Albin; D E Kuhl
Journal:  Ann Neurol       Date:  2001-09       Impact factor: 10.422

6.  Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease.

Authors:  E Donnemiller; J Heilmann; G K Wenning; W Berger; C Decristoforo; R Moncayo; W Poewe; G Ransmayr
Journal:  Eur J Nucl Med       Date:  1997-03

7.  Clinical features of neuroleptic malignant syndrome in basal ganglia disease. Spontaneous presentation in a patient with Hallervorden-Spatz disease in the absence of neuroleptic drugs.

Authors:  K Hayashi; E Chihara; T Sawa; Y Tanaka
Journal:  Anaesthesia       Date:  1993-06       Impact factor: 6.955

8.  A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping.

Authors:  Sean J Colloby; John D Fenwick; E David Williams; Sean M Paling; Kyriakos Lobotesis; Clive Ballard; Ian McKeith; John T O'Brien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-05       Impact factor: 9.236

9.  Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease.

Authors:  M A Piggott; E K Perry; E F Marshall; I G McKeith; M Johnson; H L Melrose; J A Court; S Lloyd; A Fairbairn; A Brown; P Thompson; R H Perry
Journal:  Biol Psychiatry       Date:  1998-10-15       Impact factor: 13.382

10.  Neuroleptic malignant-like syndrome: a complication of acute organophosphate poisoning.

Authors:  G Ochi; K Watanabe; H Tokuoka; S Hatakenaka; T Arai
Journal:  Can J Anaesth       Date:  1995-11       Impact factor: 5.063
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.